好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

12 versus 24 h Bed Rest After Acute Ischemic Stroke Thrombectomy: A 14-year Retrospective Cohort Study
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (11:45 AM-12:45 PM)
5-023
We aimed to evaluate whether shorter bed rest yields similar discharge outcomes, in-hospital complications, and readmission rates compared to the standard 24-hour bed rest in acute ischemic stroke (AIS) patients treated with MT +/- IV thrombolysis.

A minimum of 24-hour bed rest after mechanical thrombectomy (MT) following AIS remains widely practiced, yet its benefit over earlier mobilization is unclear.

Consecutive adult AIS patients treated with MT from January 21, 2010, until December 31, 2024, at a single stroke center were included. Standard 24-hour bed rest (before April 8, 2020) was retrospectively compared with the current 12-hour protocol.

1173 patients were included (638 ≥12h, 535 ≥24h). Mean (s.d.) age was 70.2 (14.7) and 69.2 (14.6). Median (IQR) NIHSS was 14.0 (7-20) and 15.0 (8-21). Mean (s.d.) door-to-puncture times (minutes) were 106.4 (167.9) and 116.8 (157.5). TICI ≥2b was achieved in 97.4% and 95.7% of patients (Likelihood Ratio χ2 p=0.20). Favorable discharge location was similar between groups in unadjusted χ2-test of proportions (64.1% vs 65.4%, Likelihood Ratio χ2 p=0.64) and multivariable logistic regression analysis (Wald χ2 p=0.99; adjusted OR=1.00; 95% CI=0.76:1.31). The frequency of good outcomes (mRS=0-2) by 90 days (37.3% vs. 39.8%, χ2 p=0.65) was similar. Unplanned readmission rates at 30 days (8.9 vs. 6.9%, LR χ2 p=0.43) and 90 days (19.9% vs. 15.1%, LR χ2 p=0.18) were not different. In the ≥12h group, pneumonia rates were higher (unadjusted: 8.2% vs. 5.1%, LR χ2 p=0.033; adjusted OR= 1.81 (95% CI= 1.09: 3.01), and median (IQR) length of stay was longer (6.0 days vs. 5.1 days, Wilcoxon p <0.001).

After adjustment, ≥12h bed rest following AIS treated with MT showed no significant difference in favorable discharge or readmission rates compared to ≥24h. Higher pneumonia rates and longer stays in the ≥12h group likely reflect unmeasured factors, indicating the need for randomized trials.

Authors/Disclosures
Isabella OShea
PRESENTER
Ms. OShea has nothing to disclose.
Muhammed Gunduz, MD (University of Massachusetts Medical School) Dr. Gunduz has nothing to disclose.
Nils Henninger, MD, PhD, FANA, FWSO (UMass Memorial Medical Center) Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henninger has stock in United Health. Dr. Henninger has stock in Novo Nordisk. Dr. Henninger has stock in Elli Lilly. Dr. Henninger has stock in Kenvue. Dr. Henninger has stock in Voyager. Dr. Henninger has stock in Alnylam. Dr. Henninger has stock in Entrada. The institution of Dr. Henninger has received research support from NIH. Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Verge Genomics.
Majaz Moonis, MD, FAHA, FAAN (University of Massachusetts, Department of Neurology) Dr. Moonis has nothing to disclose.
Raphael A. Carandang, MD, FAAN (University of Massachusetts Medical School/UMASS Memorial Medical Group) Dr. Carandang has nothing to disclose.
Rakhee Lalla, DO Dr. Lalla has received personal compensation in the range of $0-$499 for serving as a Consultant for Women's health initiative .
Danison Emmerson, MD (UMass Memorial Medical Center) Dr. Emmerson has nothing to disclose.
Muhammad Ramzan, MD (UMMH) No disclosure on file
Thomas Ford, MD (University of Massachusetts Medical Center) Dr. Ford has nothing to disclose.
Annie Ferris, MD (UMass Memorial Neurology Dept.) An immediate family member of Dr. Ferris has received personal compensation for serving as an employee of Immanuel Lutheran Church.
Adalia H. Jun-O'Connell, MD, MBA, FAAN (MRMC) Dr. Jun-O'Connell has received personal compensation in the range of $5,000-$9,999 for serving as a member with Women's Health Initiative.
Kayla Overly, PA Mrs. Overly has nothing to disclose.
Bruce Barton (UMass Memorial Medical Center) No disclosure on file
Brian Silver, MD, FAAN (UMass Memorial Medical Center) Dr. Silver has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Various legal firms. Dr. Silver has received intellectual property interests from a discovery or technology relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver has received personal compensation in the range of $500-$4,999 for serving as a Consultant with Women's Health Initiative. Dr. Silver has received personal compensation in the range of $500-$4,999 for serving as a Consultant with Best Doctors, Inc./Teladoc, Inc.. Dr. Silver has a non-compensated relationship as a Consultant with ABPN that is relevant to AAN interests or activities. Dr. Silver has a non-compensated relationship as a Member, Regional Board of Directors with American Heart Association that is relevant to AAN interests or activities.